

The information in this document applies to services provided during the COVID-19 public health emergency, which ends on May 11, 2023. For dates of service on or after May 12, 2023, normal business rules apply; refer to the member's benefits.

Here's what you need to know as a Blue Cross Blue Shield of Michigan and Blue Care Network provider about the authorized and available COVID-19 vaccines.

Vaccine coverage

Three vaccines, manufactured by Pfizer, Moderna and Janssen Biotech (Johnson & Johnson), have received Emergency Use Authorization from the U.S. Food and Drug Administration. The Pfizer vaccine (marketed as Comirnaty) received final and full approval by the FDA on Aug. 23, 2021. The Moderna vaccine (marketed as Spikevax) received final and full approval by the FDA on Jan. 31, 2022. The vaccine itself will be paid for through funding authorized by the Coronavirus Aid, Relief, and Economic Security (CARES) Act for everyone. Providers should not bill for the cost of the vaccine for any free, government-provided vaccine products.

Commercial products: Blue Cross and BCN are covering vaccine administration with \$0 member cost share for all commercial plans.

Medicare Advantage products: Medicare pays directly for vaccine administration for Medicare Advantage beneficiaries with \$0 member cost share in 2020 and 2021. Starting Jan. 1, 2022, follow the instructions found in the [Dec. 17, 2021, Provider Alert](#).

COVID-19 vaccine administration billing

The CPT Editorial Panel has worked with the Centers for Medicare & Medicaid Services to create new vaccine administration codes that are both distinct to each COVID-19 vaccine and the specific dose in the required schedule. Providers can use these codes to bill for administering authorized vaccines:

- *0001A – Pfizer dose 1 (12 years and older) – no longer authorized for use effective April 18, 2023
- *0002A – Pfizer dose 2 (12 years and older) – no longer authorized for use effective April 18, 2023
- *0003A – Pfizer dose 3 (12 years and older) – no longer authorized for use effective April 18, 2023
- *0004A – Pfizer booster (12 years and older) – no longer authorized for use effective April 18, 2023
- *0011A – Moderna dose 1 (12 years and older) – no longer authorized for use effective April 18, 2023
- *0012A – Moderna dose 2 (12 years and older) – no longer authorized for use effective April 18, 2023
- *0013A – Moderna dose 3 (12 years and older) – no longer authorized for use

effective April 18, 2023

- *0021A – AstraZeneca dose 1 (pending EUA approval)
- *0022A – AstraZeneca dose 2 (pending EUA approval)
- *0031A – Janssen (only 1 dose required)
- *0034A – Janssen booster
- *0041A – Novavax dose 1
- *0042A – Novavax dose 2
- *0051A – Pfizer pre-diluted dose 1 (12 years and older) – no longer authorized for use effective April 18, 2023
- *0052A – Pfizer pre-diluted dose 2 (12 years and older) – no longer authorized for use effective April 18, 2023
- *0053A – Pfizer pre-diluted dose 3 (12 years and older) – no longer authorized for use effective April 18, 2023
- *0054A – Pfizer pre-diluted booster (12 years and older) – no longer authorized for use effective April 18, 2023
- *0064A – Moderna booster (18 years and older) – no longer authorized for use effective April 18, 2023
- *0071A – Pfizer pediatric dose 1 (5 through 11 years old) – no longer authorized for use effective April 18, 2023
- *0072A – Pfizer pediatric dose 2 (5 through 11 years old) – no longer authorized for use effective April 18, 2023
- *0073A – Pfizer pediatric dose 3 (5 through 11 years old) – no longer authorized for use effective April 18, 2023
- *0074A – Pfizer pediatric booster (5 through 11 years old) – no longer authorized for use effective April 18, 2023
- *0081A – Pfizer pediatric dose 1 (6 months through 4 years old) – no longer authorized for use effective April 18, 2023
- *0082A – Pfizer pediatric dose 2 (6 months through 4 years old) – no longer authorized for use effective April 18, 2023
- *0083A – Pfizer pediatric dose 3 (6 months through 4 years old) – no longer authorized for use effective April 18, 2023
- *0091A – Moderna pediatric dose 1 (6 through 11 years old) – no longer authorized for use effective April 18, 2023
- *0092A – Moderna pediatric dose 2 (6 through 11 years old) – no longer authorized for use effective April 18, 2023
- *0093A – Moderna pediatric dose 3 (6 through 11 years old) – no longer authorized for use effective April 18, 2023
- *0094A – Moderna booster – no longer authorized for use effective April 18, 2023
- *0111A – Moderna pediatric dose 1 (6 months through 5 years old) – no longer authorized for use effective April 18, 2023
- *0112A – Moderna pediatric dose 2 (6 months through 5 years old) – no longer authorized for use effective April 18, 2023
- *0113A – Moderna pediatric dose 3 (6 months through 5 years old) – no longer authorized for use effective April 18, 2023

- *0121A – Pfizer single dose (bivalent, 12 years and older)
- *0124A – Pfizer additional dose (bivalent, 12 years and older)
- *0134A – Moderna additional dose (bivalent, 12 years and older)
- *0141A – Moderna pediatric dose 1 (bivalent, 6 months through 11 years old)
- *0142A – Moderna pediatric dose 2 (bivalent, 6 months through 11 years old)
- *0144A – Moderna additional dose (bivalent, 6 through 11 years old)
- *0151A – Pfizer pediatric single dose (bivalent, 5 through 11 years old)
- *0154A – Pfizer additional dose (bivalent, 5 through 11 years old)
- *0164A – Moderna additional dose (bivalent, 6 months through 5 years old)
- *0171A – Pfizer pediatric dose 1 (bivalent, 6 months through 4 years old)
- *0172A – Pfizer pediatric dose 2 (bivalent, 6 months through 4 years old)
- *0173A – Pfizer pediatric dose 3 (bivalent, 6 months through 4 years old)
- *0174A – Pfizer pediatric additional dose (bivalent, 6 months through 4 years old)
- M0201 – Additional payment for COVID-19 vaccine home administration (see [June 17 Provider Alert](#) for more information)

For commercial members: Providers should bill Blue Cross or BCN for administration of the vaccine using the appropriate codes. When the government-purchased supply of COVID-19 vaccines runs out, providers should bill the member's health plans for both administration and the vaccine. We'll process claims based on member's immunization benefits. For more information, see the provider alert: [COVID-19 vaccine product coverage](#). See also the provider alert: [Check coverage for COVID-19 vaccines for Blue Cross commercial members, starting April 1](#).

For Medicare Advantage members: For dates of service prior to Jan. 1, 2022, submit claims for administering COVID-19 vaccines to Original Medicare. For dates of service on or after Jan. 1, 2022, submit claims to Blue Cross or BCN for members with Medicare Plus BlueSM or BCN AdvantageSM plans. Medicare Advantage providers can refer to [Medicare Billing for COVID-19 Vaccine Shot Administration](#)** for more information on submitting claims. Some Medicare beneficiaries may not routinely carry their Medicare card. To locate a member's Medicare Beneficiary Identifier (Medicare number) without their card, use the Medicare Administrative Contractor provider portal.

Please see the [COVID-19 Vaccines and Monoclonal Antibodies](#)** site for the current list of vaccines and their corresponding billing codes and payment allowances for Medicare. For long, medium and short CPT code descriptors, please see the American Medical Association's [COVID-19 CPT vaccine and immunization codes](#)** page.

COVID-19 vaccines administered in a physician office or urgent care center

If a member visits a physician's office or urgent care center to only receive the vaccine, do not bill for an office visit.

Available vaccines and timing of administration

It's crucial to follow the vaccine intervals specified for each vaccine. For the latest recommendations, see the following sections of the [CPT® Assistant, Special Edition: May](#)

[2023 Update](#) as published by the American Medical Association.*

- Pfizer Bivalent Vaccines: Scenarios, Recommendations and CPT Codes
- Moderna Bivalent Vaccine: Scenarios, Recommendations and CPT Codes

The Janssen vaccine only requires one dose, but a booster is now recommended.

An additional vaccine dose is given to [eligible individuals](#)** when their original vaccine protection begins to wane. See also recommendations for [individuals who are immunocompromised](#)**.

Distribution of vaccines

Providers need to be enrolled with the State of Michigan to administer the vaccines. MDHHS has sent out enrollment information to providers. Providers can also find information in the *Enrollment* section of the MDHHS [COVID-19 Vaccine Provider Guidance & Educational Resources](#)** page.

Administration of vaccines

The Centers for Disease Control and Prevention is partnering with CVS and Walgreens to assist in administration of the vaccine to long-term care facilities, skilled nursing facilities and adult living facilities. Vaccines are distributed through normal vaccine distribution mechanisms directly to enrolled providers in appropriate phases.

Home health agencies can administer the COVID-19 vaccine in the home for eligible patients. Blue Cross and BCN are following the Centers for Medicare & Medicaid Services' guidelines for determining which patients qualify for in-home COVID-19 vaccination. For more information, see the [June 17, 2021 Provider Alert](#).

Reporting COVID-19 vaccine administration

COVID-19 vaccination providers must report their vaccine inventory daily, document administration in their medical record systems within 24 hours of administration, and use their best efforts to report administration data to the relevant system for the jurisdiction as soon as practicable and no later than 72 hours after administration. Michigan providers should use the Michigan Care Improvement Registry. Read more on the CDC [COVID-19 Vaccination Provider Support](#)** page.

For your patients

During the vaccination process, you must provide:

- An Emergency Use Authorization (EUA) fact sheet or Vaccine Information Statement (VIS), as applicable, to each vaccine recipient/parent/legal guardian prior to vaccination. Fact sheets are available on the [FDA website](#)** (see the list under the *Vaccines* blue box section).
- A COVID-19 vaccination record card to each vaccine recipient/parent/legal guardian. The card provides room for a written reminder for a second-dose appointment. Please see the *Patient Education & Adverse Event Reporting* section of the [MDHHS COVID-19 Vaccine Information for Providers](#)** document for details. Encourage patients to take a photo of this card with their smartphone and add the

second dosage date in their calendar. Patients can also receive a text message reminder for their second dose. They can sign up through the [CDC v-safeSM after vaccination health checker tool](#)^{**}. MDHHS is developing their text messaging system. MDHHS may also implement second-dose postcard reminders sent to patients.

Where to find more information

- From the CDC:
 - [Coronavirus Disease 2019 \(COVID-19\): Vaccines](#)^{**}
 - [COVID-19 Vaccination Training and Educational Materials](#)^{**}
- [CMS COVID-19](#)^{**}
- From the MDHHS:
 - [COVID-19 Vaccine](#)^{**} (then click *More Information* under the *Provider Guidance & Education* section)
 - [COVID-19 Vaccine Dashboard](#)^{**}
- [MI Blues Perspectives COVID-19 Vaccines: What You Should Know](#)

None of the information included herein is intended to be legal advice and as such it remains the provider's responsibility to comply with all applicable state and federal laws and regulations, including all coding and documentation requirements.

***CPT Copyright 2022 American Medical Association. All rights reserved. CPT[®] is a registered trademark of the American Medical Association**

****Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're required to let you know we're not responsible for its content.**